Efficacy and Cost Effectiveness Analysis of Five Different Therapeutic Schemes for Chronic Hepatitis B
- VernacularTitle:慢性乙肝5种治疗方案的临床疗效及成本效果分析
- Author:
Zhenman WEI
;
Wenjin ZHANG
;
Lipin LIU
- Publication Type:Journal Article
- Keywords:
Chronic Hepatitis B;
Cost-effectiveness analysis;
Efficacy;
Interferon;
Lamivudine;
Thymotentin;
Thymosin alphal
- From:
Journal of Chinese Physician
2001;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and the economic effectiveness of different therapeutic schemes for Chronic hepatitis UB.Methods Patients with Chronic Hepatitis B were treated by using different drugs:Interferon ?1b(group A),Lamivudine(group B),Interferon ?1b combination with Lamivudine(group C),Interferon ?1b combination with thymotentin(group D),Interferon ?1b combination with thymosin alphal(group E).Evaluation was carried out with pharmacoeconomic cost-effectiveness.Results At the end of therapy,the clearance rate of serum HbeAg was lowest in group B(10 94%),the other groups were more than 50%.The clearance rate of serum HBV-DNA was higher in group B and C than in the other groups,it was 85 94%,87 93% respectively.Normalizing ALT values was higher in group C,group D and group E than in group A and group B.The costs of several therapeutic schemes were RMB 8156 7(group A),6935(group B),15091 7(group C),26033 4(group D) and 89978 4(group E) yuans,respectively.Conclusions According to the evaluation with pharmacoeconomic cost-effectiveness analysis,the therapeutic scheme of Interferon ?1b,Lamivudine and Interferon ?1b combination with Lamivudine is best one for treating chronic hepatitsi B,in this groups,Interferon ?1b combination with Lamivudine was better than the other two groups.
